- Home
- BLRX vs BCAB Comparison
BLRX vs BCAB Comparison
Compare BLRX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | BCAB |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 7.4M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BLRX | BCAB |
|---|---|---|
| Price | $2.31 | $4.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 15.6K | ★ 850.7K |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.12 |
| 52 Week High | $7.77 | $6.52 |
Technical Indicators
Market Signals| Indicator | BLRX | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 78.12 |
| Support Level | $2.15 | $0.36 |
| Resistance Level | $3.93 | $6.52 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | 0.01 | 0.45 |
| Stochastic Oscillator | 30.19 | 66.88 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.